🇺🇸 Lederfolin in United States
408 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 408
Most-reported reactions
- Neutropenia — 60 reports (14.71%)
- Thrombocytopenia — 54 reports (13.24%)
- Pyrexia — 50 reports (12.25%)
- Anaemia — 41 reports (10.05%)
- Diarrhoea — 41 reports (10.05%)
- Off Label Use — 37 reports (9.07%)
- Vomiting — 34 reports (8.33%)
- Paraesthesia — 32 reports (7.84%)
- Asthenia — 30 reports (7.35%)
- Infusion Related Reaction — 29 reports (7.11%)
Other Other approved in United States
Frequently asked questions
Is Lederfolin approved in United States?
Lederfolin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Lederfolin in United States?
University of Pisa is the originator. The local marketing authorisation holder may differ — check the official source linked above.